## Supplementary Table S4 – Pharmacokinetics of selected 2-(thio)oxothiazolidin-4-one (LJ001) and oxazolidine dithiones (JL103, JL118, JL122)

Drug	Dose	Dose Level	C <sub>P</sub> or C <sub>max</sub> <sup>a</sup>	T <sub>max</sub>	AUClast	AUCinf	MRT <sub>last</sub>	t <sub>1/2</sub>	F	Ve	Cle
	Route	(mg/kg)	(ng/ml)	(hr)	(hr•ng/ml)	(hreng/ml)	(hr)	(hr)	(%)	(L/kg)	(ml/hr/kg)
LJ-001	iv	10	767.0	0.08	238	241	0.2	0.2	NAc	9.1	41549
	ip	5	56.2	0.08	15	17	0.2	0.2	14.1	9.1	41825
	ро	10	7.9 <sup>b</sup>	0.5	NC	$NC^d$	NC	NC	NC	NC	NC
	ро	100	5.4 <sup>b</sup>	0.08	NC	NC	NC	NC	NC	NC	NC
JL-103	iv	10	16167.0	0.08	6464	6498	1.1	2.2	NA	4.8	1539
	ip	10	612.7	0.5	2894	2959	4.2	4.1	45.5	9.1	1538
	ро	10	1126.7	1	3093	3115	2.3	1.6	47.9	3.6	1538
	ро	100	417.0	1	1947	1986	3.6	2.2	3.1	4.9	1561

<sup>&</sup>lt;sup>a</sup> C<sub>P</sub> is the first measured plasma concentration for iv groups.

<sup>&</sup>lt;sup>e</sup> For ip and po groups, V and CI were calculated from F•(V/F) and F•(Cl/F), respectively.

Test		Dose	C <sub>max</sub>	$T_{\text{max}}$	<b>AUC</b> <sub>last</sub>	<b>AUC</b> inf	MRT <sub>last</sub>	t <sub>1/2</sub>	V/F	CI/F
Compound	Route	(mg/kg)	(ng/ml)	(hr)	(hr*ng/ml)	(hr*ng/ml)	(hr)	(hr)	(L/kg)	(ml/hr/kg)
JL-118	ip	1.25	626	0.5	1835	2247.92	5.3	16.0	12.8	556.1
JL-118	ро	10	253	1	1347.67	NCª	8.8	NC <sup>a</sup>	NC <sup>a</sup>	NCª
	ро	50	122	0.5	841.24	NCa	9.8	NC a	NC a	NCa
	ро	100	124	0.5	1159.83	NCª	11.4	NC <sup>a</sup>	NCª	NCª
JL-122	ip	5	122	0.5	568.61	NC <sup>a</sup>	5.5	NC <sup>a</sup>	NC <sup>a</sup>	NC <sup>a</sup>
	ip	10	132	0.25	924.18	NC <sup>a</sup>	6.2	NC <sup>a</sup>	NC <sup>a</sup>	NCª
JL-122	ро	10	99.3	0.5	231.79	NC <sup>a</sup>	4.7	NC <sup>a</sup>	NC <sup>a</sup>	NC <sup>a</sup>
	ро	100	287	1	1271.74	$NC^a$	7.0	NC <sup>a</sup>	NC <sup>a</sup>	NCa

<sup>&</sup>lt;sup>a</sup> NC - Not calculated, due to limited ( $\leq 2$ ) number of time-points with measurable plasma concentrations in the terminal elimination phase after  $T_{max}$  or a poor fit ( $r^2 \leq 0.8$ ) for the straight line portion in the terminal elimination phase

iv: intravenous. ip: intraperitoneal. po: per os (oral).  $C_p$ : plasma concentration.  $C_{max}$ : observed maximum plasma concentration after administration.  $T_{max}$ : time to reach  $C_{max}$ . AUC<sub>last</sub>: area under the concentration-time curve up to the last measurable concentration. AUC<sub>inf</sub>: AUC curve to infinite time. MRT<sub>last</sub>: mean residence time of the drug in the systemic circulation from 0 to last time point.  $t_{1/2}$ : terminal half-life. F: absolute bioavailability. V: volume of distribution. Cl: total plasma serum or blood clearance of drug.

<sup>&</sup>lt;sup>b</sup> There was only one sample with detectable drug levels.

<sup>&</sup>lt;sup>c</sup> NA = not applicable.

<sup>&</sup>lt;sup>d</sup> NC = not calculated. There were insufficient data points for calculation of parameter.